MHRA: Tibolone (Livial) increases risk of breast cancer recurrence
The Medicines and Healthcare products Regulatory Agency (UK) warned in the February 2009 Drug Safety Advice about the increased breast cancer recurrence in patients treated with tibolone (Livial):...
View ArticleMetoclopramide and tardive dyskinesia: FDA adds boxed warning
The FDA issued a press release (dated February 26, 2009) in which they announce that the agency will require Metoclopramide (Maxolon, Reglan, Degan, Maxeran, Primperan, and Pylomid) manufacturers to...
View ArticleAtomoxetine (Strattera) for ADHD: risk of psychotic or manic symptoms
The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for March 2009. One of the drugs reviewed is atomoxetin (Strattera), a norepinephrine reuptake inhibitor...
View ArticleFDA video warning about local anesthetics side effects
Local anesthetics side effects are covered in the March 2009 edition of FDA’s Patient Safety News. The agency’s concern is that after a study published in the the journal Radiology in which the...
View ArticleMore evidence that bisphosphonates do not increase the risk of atrial...
Bisphosphonates don’t increase the risk of atrial fibrillation, according to the study Oral Bisphosphonates and Risk of Atrial Fibrillation and Flutter in Women: A Self-Controlled Case-Series Safety,...
View ArticleClik here to view.
FDA video: interaction of IV ceftriaxone with calcium-containing products
The FDA updated the full prescribing information of ceftriaxone (Rocephin and generics). This is an update to a previous ( september 2007) alert on the risk of interaction between ceftriaxone and...
View ArticleEMA: Use modafinil only for narcolepsy
The European Medicines Agency recommended restricting the use of modafinil for narcolepsy only. “The European Medicines Agency has recommended restricting the use of modafinil-containing medicines. The...
View Article
